37results about How to "Prolong the mean survival time" patented technology

The present invention relates to the use of live mycobacterium of the M. tuberculosis complex for preparing a medicament, wherein the function of the zmp1-gene is inactivated, pharmaceutical compositions prepared from such mycobacteria as well as a method for the treatment and / or prophylaxis of a disease or medical condition using said pharmaceutical composition.

The invention relates to a method for constructing a motor dysfunction phenotype GTPCH enzyme deficiency mouse model. The construction includes: (1) obtaining Gch1 p.Leu108Arg heterozygous mutant mice, the leucine codon at position 108 of the Gch1 gene of the heterozygous mutant mice is mutated into an arginine codon; (2) The heterozygous mutant mice are crossed with wild-type mice of other strains to screen the F1 generation heterozygous mutant mice; (3) the F1 generation heterozygous mutant mice are selfed to screen the F2 generation homozygous mutant mice. This construction method can avoid the lethal problem during the development of GTPCH enzyme-deficient embryos, and the birth rate of homozygous mutant mice can reach or approach Mendel's expected ratio. At the same time, the crossbreeding of mice with different genetic backgrounds can also improve the survival of F2 generation mice after birth and prolong the average survival period.

The invention discloses a preparation method for a Shiqi exogenous preparation. The Shiqi exogenous preparation comprises the following raw materials: holly root, berchemia lineata, rose apple, fragrant glory-bower and pandanaceae pandanus tectorius. The preparation method is characterized by comprising the following steps: taking the raw materials, adding 50-80% of ethanol or water and carrying out low-temperature ultrasonic extraction for 5-6 times, filtering, combining filtrates, and carrying out low-temperature reduced pressure concentration. The invention further discloses an application of the Shiqi exogenous preparation prepared by the method in preparation of related anti-influenza virus medicines. The Shiqi exogenous preparation obtained by the preparation method disclosed by the invention has a better anti-virus activity.

The invention relates to an analogue virus, in particular to an FAT10 gene siRNA recombination analogue virus as well as a preparation method and application thereof. The analogue virus is a compound of a fusion peptide and an FAT10 gene siRNA recombination expression vector, wherein the fusion peptide is formed by connecting an RGD peptide and a cell-penetrating peptide HIV-Tat49-57; and the FAT10 gene siRNA recombination expression vector controls the expression of the FAT10 gene siRNA through an alpha fetoprotein promoter. The analogue virus can target hepatocarcinoma cells and limit the expression of the FAT10 gene siRNA in the hepatocarcinoma cells and cause silent expression of the FAT10 gene in the hepatocarcinoma cells because of the specificity to avoid the damage to the irrelevant cells, and has the advantages of high transfection efficiency, simple and time-saving preparation method, and the like. The analogue virus can be used for preparing anti-cancer drugs and has good prospect in development and application in the field of the gene therapy of liver cancers.

The present invention relates to the technical field of medicines, particularly to applications of celastrol. The invention provides applications of celastrol in preparation of influenza virus inhibitors and drugs for prevention and / or treatment of influenza virus diseases. According to the present invention, the experimental results show that the celastrol can significantly reduce the mouse death caused by influenza virus infection and prolong the average survival time of the mice, can significantly inhibit mouse lung infection caused by influenza virus infection and effectively relieve the lung infection symptoms of the mice, can treat influenza, pneumonia and other respiratory tract infection diseases caused by influenza virus, can prevent the proliferation and the spread of viruses in vivo and protect normal tissue from injury, and can prevent the occurrence of viral infectious diseases.

The invention discloses novel application of the pure traditional Chinese medicine preparation basil polysaccharide, namely application of basil polysaccharide as taxol synergist in preparing antineoplastic drugs. As proved by research findings, combination of basil polysaccharide and taxol has the functions of inhibiting proliferation and activity of tumour cells (including lung cancer, laryngocarcinoma, stomach cancer and the like) from different tissue sources; in addition, according to a basil polysaccharide extracorporal cell experiment, the working concentration is free of toxicity, and basil polysaccharide is dose-dependent on the synergism of the taxol and has a clinical application prospect.

The invention discloses a Livin-based immunostimulatory complex, which is composed of a recombinant eukaryotic vector co-expressed with two genes of Livin and IgG Fc segment, a CpG motif, saponin QuilA, cholesterol and lecithin; the preparation method is at a pH of 7.2~ In the phosphate buffer solution of 7.4, add the recombinant eukaryotic vector with the final concentration of 0.5mg / mL of Livin and IgGFc double gene co-expression, 0.1mg / mL of CpG motif, 1mg / mL of saponin QuilA, 0.1mg / mL of Cholesterol and 0.1mg / mL lecithin, ultrasonic treatment in an ice bath to fully mix and emulsify the solution, and then dialyze with PBS, the obtained microfloccules are the immunostimulatory complex based on the Livin gene; the immunostimulatory complex can be large Significantly improve the immunogenicity of Livin, and co-incubating it with dendritic cells can stimulate the maturation and activation of dendritic cells and exert an efficient antigen presentation ability, thereby efficiently inducing the cytotoxic killing effect of CTL and effectively inhibiting glial cells The growth of the tumor, prolonging the average survival period of tumor-bearing nude mice and improving the average survival rate can be used to prepare dendritic cell therapeutic vaccine against glioma.